Neuroendocrine Neoplasia of the Female Genital Tract

Talia, Karen L.; Ganesan, Raji

doi:10.1016/j.path.2022.02.012

Cited by 5 publications

(6 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, necrosis is often observed in LCNEC cases. 1 The presented case in this study exhibited the typical morphological features consistent with LCNEC.…”

Section: Discussionsupporting

confidence: 62%

“…The p53 protein exhibited a wild-type pattern, while the nuclear stains for SMARCB1/INI-1 and SMARCA4 were retained. 1 – 8 …”

Section: Discussionmentioning

confidence: 99%

“…In addition, neuroendocrine neoplasia is very poorly understood. 1 Thus far, only 25 cases of pure primary ovarian large-cell neuroendocrine carcinoma (LCNEC) have been reported in English literature. 1 – 8 To the best of our knowledge, only one reported case had a confirmed BRAC2 germline mutation through molecular testing.…”

Section: Introductionmentioning

confidence: 99%

“… 1 Thus far, only 25 cases of pure primary ovarian large-cell neuroendocrine carcinoma (LCNEC) have been reported in English literature. 1 – 8 To the best of our knowledge, only one reported case had a confirmed BRAC2 germline mutation through molecular testing. 2 In the present study, we introduce another unique case of pure large-cell neuroendocrine carcinoma (pLCNEC) of the ovary, which is the first one reported with the BRAC1 somatic mutation.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Pure large-cell neuroendocrine carcinoma of the ovary with a somatic BRCA1 mutation: The first reported case and the review of the literature

Wang,

Gao,

Wang

et al. 2024

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Pure large-cell neuroendocrine carcinomas of the ovary are extremely rare, so there is a lack of molecular information on this type of cancer. Herein, we presented a pure primary large-cell neuroendocrine carcinomas of the ovary in a 72-year-old female with a pathogenic somatic mutation at the c.5332+1g>a splice site of the BRCA1 gene and with no TP53 mutation. She was uneventful 32 months after the operation and chemotherapies. To the best of our knowledge, this is the first report of a BRCA1 somatic mutation in the ovary large-cell neuroendocrine carcinomas. Testing BRCA1/2 mutations in patients with large ovarian cell neuroendocrine carcinomas might provide an opportunity for their future target treatments. It would expand our understanding.

show abstract

“…In addition, necrosis is often observed in LCNEC cases. 1 The presented case in this study exhibited the typical morphological features consistent with LCNEC.…”

Section: Discussionsupporting

confidence: 62%

“…The p53 protein exhibited a wild-type pattern, while the nuclear stains for SMARCB1/INI-1 and SMARCA4 were retained. 1 – 8 …”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pure large-cell neuroendocrine carcinoma of the ovary with a somatic BRCA1 mutation: The first reported case and the review of the literature

Wang,

Gao,

Wang

et al. 2024

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

show abstract

“…Small-cell neuroendocrine carcinoma of the cervix (SCNCC) is a rare pathological type of cervix neoplasm with highly aggressive biological behaviors and poorer prognosis than the most common counterpart with squamous carcinoma [1,2]. Several different names were used in the past and now it is considered a high-grade malignancy classified as neuroendocrine carcinoma along with carcinoid tumor, atypical carcinoid tumor, and large cell neuroendocrine tumor [3].…”

mentioning

confidence: 99%

The impact of neo/adjuvant treatment choices on prognosis for surgically treated small-cell neuroendocrine carcinoma of the cervix

Zhao,

Sun,

Yang

et al. 2024

neo

View full text Add to dashboard Cite

Small-cell neuroendocrine carcinoma of the cervix (SCNCC) is a rare and aggressive tumor with a poor prognosis. Surgical resection followed by adjuvant therapy is the standard treatment for early-stage disease but the influence of different neo/adjuvant treatment approaches remains unclear. Retrospectively, we collected patients' characteristics and treatments in two medical centers. Disease status and survival outcomes were renewed through follow-up. Statistics analysis mainly included Kaplan-Meier methods for survival curve estimation, log-rank test for survival curve comparison, and Cox proportional hazards models for independent prognostic factors prediction. Finally, 51 patients treated by radical surgery between January 2010 and April 2020 were enrolled with a median age of 50 years (range: 32-68). 12 (23.5%) patients were at stage IIIC1 according to the International Federation of Gynecology and Obstetrics (FIGO) 2018 staging systems and the rest were at the early stage. The mean tumor size was 3.6±1.3 cm. Pathological examination found 24 cases with pure SCNCC and 27 cases with admixed SCCC. 29 (56.9%) patients had deep stromal infiltration and 19 (37.3%) patients had lymphovascular space invasion. 34 (66.7%) patients received neo/adjuvant chemotherapy and pelvic radiation was conducted in 41 (80.39%) patients with a median dose of 46 Gy (range: 40-50.4 Gy). The median follow-up time was 25.0 months. The median disease-free survival (DFS) time was 23.0 months. 27 (52.9%) patients developed distant metastasis and 14 (27.5%) experienced local failure. The median overall survival (OS) was 32.0 months. Univariate and multivariate analysis showed neoadjuvant chemotherapy as negative (HR=2.081, 95% CI 1.030-4.203, p=0.041) and adjuvant chemotherapy (HR=0.409, 95% CI 0.213-0.784, p=0.020) as positive independent prognostic factor for DFS. For OS, only lymph node metastasis was confirmed as an independent prognostic factor in both univariate analysis (HR=1.528, 95% CI 1.011-2.308, p=0.044) and multivariate analysis (HR=1.697, 95% CI 1.041-2.768, p=0.034). In conclusion, for surgically treated SCNCC, adjuvant chemotherapy showed a positive influence on DFS while neoadjuvant chemotherapy harmed DFS. OS was unaffected by either treatment choice.

show abstract

Primary neuroendocrine neoplasms of the vulva: A review of the MITO rare cancer group

Barcellini,

Golia D’Augè,

Mandato

et al. 2024

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Neuroendocrine Neoplasia of the Female Genital Tract

Cited by 5 publications

References 56 publications

Pure large-cell neuroendocrine carcinoma of the ovary with a somatic BRCA1 mutation: The first reported case and the review of the literature

Pure large-cell neuroendocrine carcinoma of the ovary with a somatic BRCA1 mutation: The first reported case and the review of the literature

The impact of neo/adjuvant treatment choices on prognosis for surgically treated small-cell neuroendocrine carcinoma of the cervix

Primary neuroendocrine neoplasms of the vulva: A review of the MITO rare cancer group

Contact Info

Product

Resources

About